UNSPSC 85893832: Low dose rate (ldr) brachytherapy of prostate using cesium 137 (cs-137)

This classification denotes the group of activities that yields a radiation therapy intervention or procedure of low dose rate (ldr) brachytherapy of prostate using cesium 137 (cs-137). This intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code DV10B7Z

UNSPSC 85893832 Low dose rate (ldr) brachytherapy of prostate using cesium 137 (cs-137) is a Commodity code that shows no relevant recent state and local procurement activity. The single posted opportunity under this code—a County of Santa Clara Health System RFQ for temporary health professional staffing services across ancillary clinical categories including audiology, cardiology, diagnostic imaging, gastroenterology, ophthalmology, orthopedic services, respiratory care, sterile processing, surgical/operating room, and therapy services—is plainly unrelated to prostate brachytherapy or cesium-based radiation therapy. The staffing solicitation addresses temporary clinical labor across multiple specialties, not the specialized oncology equipment, materials, or procedural services that the code's nominal scope describes. This mismatch suggests either a coding error in the source data or genuine absence of state and local brachytherapy procurement under this taxonomy in the recent window.

State and local governments do solicit cancer treatment services and oncology support through procurement channels, but if prostate brachytherapy work exists under this or related codes, it is not reflected in the recent opportunities available. Bidders should verify whether state and local health systems and cancer treatment centers in their target regions use this code, related UNSPSC codes, or alternative taxonomies (such as healthcare service line codes or equipment procurement categories) when soliciting brachytherapy or radiation oncology work. Without current activity data, the code presents minimal near-term pursuit opportunity unless your firm has intelligence on pending or forecast demand from specific state health departments, county hospital systems, or regional cancer treatment networks.